HLS Therapeutics Inc. updated consolidated revenue guidance for the full year 2024. for the year, the company is lowering its full year consolidated revenue guidance to a range of $60 million - $62 million from $63.5 million -$66.5 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.35 CAD | +1.52% | -4.83% | -15.19% |
Jun. 07 | Transcript : HLS Therapeutics Inc. - Shareholder/Analyst Call | |
May. 28 | HLS Therapeutics Notes Role of Pharmaceutical Support Programs on Persistence with Clozapine Treatment in Quebec Study | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.19% | 77.62M | |
+30.23% | 78.37B | |
+3.26% | 25.35B | |
+15.18% | 8.8B | |
+8.31% | 8.37B | |
-27.86% | 7.34B | |
+1.17% | 4.14B | |
-9.21% | 3.78B | |
-5.60% | 3.5B | |
+11.43% | 3.33B |
- Stock Market
- Equities
- HLS Stock
- News HLS Therapeutics Inc.
- HLS Therapeutics Inc Updates Consolidated Revenue Guidance for the Full Year 2024